Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2022

Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma

Résumé

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) characterized by the translocation t(11;14) (q13;q32) and a poor response to rituximab–anthracycline-based chemotherapy. High-dose cytarabine-based regimens offer a durable response, but an important number of MCL patients are not eligible for intensive treatment and are ideal candidates for novel targeted therapies (such as BTK, proteasome or BCL2 inhibitors, Immunomodulatory Drugs (IMiDs), bispecific antibodies, or CAR-T cell therapy). On the bench side, several studies aiming to integrate the tumor within its ecosystem highlighted a critical role of the tumor microenvironment (TME) in the expansion and resistance of MCL. This led to important insights into the role of the TME in the management of MCL, including potential targets and biomarkers. Indeed, targeted agents often have a combined mechanism of action on the tumor B cell but also on the tumor microenvironment. The aim of this review is to briefly describe the current knowledge on the biology of the TME in MCL and expose the results of the different therapeutic strategies integrating the TME in this disease.
Fichier principal
Vignette du fichier
2022_revue-Cancers_Sarkozy.pdf (366.65 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03745694 , version 1 (04-08-2022)

Identifiants

Citer

Khalil Saleh, Morgane Cheminant, David Chiron, Barbara Burroni, Vincent Ribrag, et al.. Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. Cancers, 2022, 14 (13), pp.3229. ⟨10.3390/cancers14133229⟩. ⟨hal-03745694⟩
60 Consultations
77 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More